URGN — Urogen Pharma Cashflow Statement
0.000.00%
Last trade - 00:00- $530.70m
- $418.09m
- $90.40m
- 52
- 13
- 55
- 34
Annual cashflow statement for Urogen Pharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -128 | -111 | -110 | -102 | -127 |
| Depreciation | |||||
| Non-Cash Items | 30.1 | 39.4 | 27.6 | 21.7 | 24.9 |
| Other Non-Cash Items | |||||
| Changes in Working Capital | -7.91 | -14.3 | -6.31 | 3.34 | 4.88 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Taxes Payable | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -106 | -84.9 | -87.6 | -76.4 | -96.8 |
| Capital Expenditures | -1.22 | -0.752 | -0.254 | -0.194 | -0.295 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 94.5 | 4.82 | 1.31 | -0.759 | -20.3 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | 93.2 | 4.07 | 1.06 | -0.953 | -20.6 |
| Financing Cash Flow Items | -0.066 | 72.3 | -0.16 | 0 | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 16.5 | 72.3 | 97.1 | 117 | 195 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 3.88 | -8.5 | 10.6 | 39.6 | 77.2 |